Robert W. Baird Lowers Price Target for HCA Healthcare Stock

Analysts cite concerns about the healthcare provider's future performance.

Apr. 15, 2026 at 1:37pm

Got story updates? Submit your updates here. ›

An extreme close-up of gears, levers, and other heavy industrial components in muted tones of steel grey and black, conceptually representing the institutional power and security of the healthcare finance sector.A dramatic, industrial-style image captures the complex machinery that underpins the healthcare finance industry, hinting at the economic forces shaping the future of major providers like HCA Healthcare.Today in Nashville

Equity research firm Robert W. Baird has lowered its price target for HCA Healthcare (NYSE: HCA) stock from $450.00 to $442.00 and maintained a 'neutral' rating on the shares. The analysts cited a less optimistic outlook for the healthcare provider's future performance.

Why it matters

HCA Healthcare is one of the largest hospital operators in the United States, so changes to its stock price target by major research firms can impact investor sentiment and the company's valuation. This move by Baird reflects broader concerns about the healthcare industry's outlook amid economic uncertainty.

The details

In a note to investors, the Baird analysts said they have reduced their price target for HCA Healthcare from $450.00 to $442.00 per share. They maintained their 'neutral' rating on the stock, indicating a potential downside of 11.41% from the company's previous closing price. The analysts did not provide specific details on the reasons behind their more cautious outlook for HCA Healthcare's future performance.

  • The updated price target and rating were issued on Wednesday, April 15, 2026.

The players

Robert W. Baird

An equity research firm that covers HCA Healthcare and has lowered its price target and rating on the stock.

HCA Healthcare

A major for-profit hospital operator headquartered in Nashville, Tennessee.

Got photos? Submit your photos here. ›

The takeaway

This price target reduction by a prominent research firm reflects broader concerns about the outlook for the healthcare industry and HCA Healthcare's future performance. Investors will be closely watching the company's upcoming financial results and guidance to gauge whether these worries are warranted.